136 related articles for article (PubMed ID: 3447935)
41. Proof of the linearity of the pharmacokinetics of alinidine in man.
Arndts D; Warnkross H; Rominger KL; Justus H
Eur J Clin Pharmacol; 1981; 21(3):201-7. PubMed ID: 7318879
[TBL] [Abstract][Full Text] [Related]
42. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.
Stopfer P; Marzin K; Narjes H; Gansser D; Shahidi M; Uttereuther-Fischer M; Ebner T
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1051-61. PubMed ID: 22200729
[TBL] [Abstract][Full Text] [Related]
43. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
44. The absorption, tissue distribution and excretion of di-n-octyltin dichloride in rats.
Penninks AH; Hilgers L; Seinen W
Toxicology; 1987 Apr; 44(1):107-20. PubMed ID: 3564046
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics and metabolism of cyclosporin G in humans.
Mangold JB; Schran HF; Tse FL
Drug Metab Dispos; 1994; 22(6):873-9. PubMed ID: 7895604
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of bethanidine in hypertensive patients.
Shen D; Gibaldi M; Israili A; Bellward G; Cunningham R; Throne M; Dayton P; McNay J
Clin Pharmacol Ther; 1975 Mar; 17(3):363-73. PubMed ID: 1120401
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
Mukai H; Sugimoto T; Ago M; Morino A
Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
[TBL] [Abstract][Full Text] [Related]
48. Tizanidine for spasticity.
Med Lett Drugs Ther; 1997 Jul; 39(1004):62-3. PubMed ID: 9217694
[No Abstract] [Full Text] [Related]
49. Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.
Karjalainen MJ; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2007 Sep; 63(9):829-36. PubMed ID: 17618427
[TBL] [Abstract][Full Text] [Related]
50. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers.
Stangier J; Schmid J; Türck D; Switek H; Verhagen A; Peeters PA; van Marle SP; Tamminga WJ; Sollie FA; Jonkman JH
J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1312-22. PubMed ID: 11185629
[TBL] [Abstract][Full Text] [Related]
51. Involvement of imidazoline receptors in the centrally acting muscle-relaxant effects of tizanidine.
Honda M; Sekiguchi Y; Sato N; Ono H
Eur J Pharmacol; 2002 Jun; 445(3):187-93. PubMed ID: 12079683
[TBL] [Abstract][Full Text] [Related]
52. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.
Cossum PA; Sasmor H; Dellinger D; Truong L; Cummins L; Owens SR; Markham PM; Shea JP; Crooke S
J Pharmacol Exp Ther; 1993 Dec; 267(3):1181-90. PubMed ID: 8166890
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics and metabolism of nateglinide in humans.
Weaver ML; Orwig BA; Rodriguez LC; Graham ED; Chin JA; Shapiro MJ; McLeod JF; Mangold JB
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):415-21. PubMed ID: 11259325
[TBL] [Abstract][Full Text] [Related]
54. Mass balance study of [14C] rabeprazole following oral administration in healthy subjects.
Setoyama T; Drijfhout WJ; van de Merbel NC; Humphries TJ; Hasegawa J
Int J Clin Pharmacol Ther; 2006 Nov; 44(11):557-65. PubMed ID: 17176622
[TBL] [Abstract][Full Text] [Related]
55. Disposition of orally administered 14C-prednimustine in cancer patients.
Gaver RC; Deeb G; Pittman KA; Issell BF; Mittelman A; Smyth RD
Cancer Chemother Pharmacol; 1983; 11(3):139-43. PubMed ID: 6640823
[TBL] [Abstract][Full Text] [Related]
56. 14C-NaVP and 14C-PEV repeated dose study in rat. Pharmacokinetic study in rats after repeated oral administrations of 14C-valproic acid sodium salt and 14C-valproic acid pivaloyl oxymethyl ester.
Bertolino M; Acerbi D; Canali S; Giachetti C; Poli G; Ventura P; Zanolo G
Eur J Drug Metab Pharmacokinet; 1998; 23(2):223-9. PubMed ID: 9725486
[TBL] [Abstract][Full Text] [Related]
57. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil.
Muirhead GJ; Rance DJ; Walker DK; Wastall P
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):13S-20S. PubMed ID: 11879255
[TBL] [Abstract][Full Text] [Related]
58. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics.
Momo K; Homma M; Osaka Y; Inomata S; Tanaka M; Kohda Y
J Clin Pharmacol; 2010 Mar; 50(3):331-7. PubMed ID: 19789372
[TBL] [Abstract][Full Text] [Related]
59. The effect of tizanidine on maximal electroshock seizures (MES) in mice.
Denizbaşi A; Berkman K; Ozyazgan S; Eşkazan E
Gen Pharmacol; 1999 Apr; 32(4):513-6. PubMed ID: 10323494
[TBL] [Abstract][Full Text] [Related]
60. Chitosan lactate wafer as a platform for the buccal delivery of tizanidine HCl: in vitro and in vivo performance.
El-Mahrouk GM; El-Gazayerly ON; Aboelwafa AA; Taha MS
Int J Pharm; 2014 Jun; 467(1-2):100-12. PubMed ID: 24680961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
